Buchumschlag

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Ivan Arcari, Francesca Colapietro, Nicola Pugliese
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Intestinal Ultrasound‐Prioritising Progress
von: Kacie H. Denton, et al.
Veröffentlicht: (2026)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
von: Yaomin Wang, et al.
Veröffentlicht: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
von: Zhuo Li, et al.
Veröffentlicht: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
von: Min Wu, et al.
Veröffentlicht: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
von: Wenjun Meng, et al.
Veröffentlicht: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
von: Sung Won Chung, et al.
Veröffentlicht: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
von: Mohamed I. Elsaid, et al.
Veröffentlicht: (2024)

Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients
von: Anna Fettiplace, et al.
Veröffentlicht: (2024)

Review article: Oesophageal disorders in chronic liver disease
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
von: Deepak Joshi, et al.
Veröffentlicht: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
von: Jiamei Wang, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
von: Mingsi Zhang, et al.
Veröffentlicht: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
von: David Uihwan Lee, et al.
Veröffentlicht: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
von: Parminder Kaur, et al.
Veröffentlicht: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Letter: The use of large language models as medical chatbots in digestive diseases
von: Hinpetch Daungsupawong, et al.
Veröffentlicht: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
von: Basile Njei, et al.
Veröffentlicht: (2024)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
von: Felicity R. Williams, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
von: Chen‐Pi Li, et al.
Veröffentlicht: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
von: Maryam Kharal, et al.
Veröffentlicht: (2024)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis. Authors' Reply
von: Pierfrancesco Visaggi, et al.
Veröffentlicht: (2026)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
von: Nipun Verma, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
von: Elliot B. Tapper, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
von: Jian Wang, et al.
Veröffentlicht: (2024)